Edwards Lifesciences Corporation $EW Shares Sold by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 214,240 shares of the medical research company’s stock after selling 10,066 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $16,756,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of EW. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the second quarter worth approximately $889,000. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $1,760,000. Arkadios Wealth Advisors bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $300,000. Randolph Co Inc acquired a new position in Edwards Lifesciences during the 2nd quarter worth $301,000. Finally, Mirova US LLC grew its stake in shares of Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Wells Fargo & Company boosted their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Up 2.2%

Shares of NYSE:EW opened at $85.85 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market capitalization of $49.82 billion, a price-to-earnings ratio of 12.35, a PEG ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.21. The company has a 50 day moving average price of $78.52 and a 200 day moving average price of $77.93.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.